Craft
ZAI Lab

ZAI Lab

Revenue

$144.3 M

FY, 2021

Market Capitalization

$4.7 B

2023-01-20

ZAI Lab Summary

Company summary

Overview
Zai Lab is a biopharmaceutical company dedicated to discovering, developing, and commercializing medicines for cancer, autoimmune and infectious diseases. It offers Zejula, a selective small-molecule poly (ADP-ribose) PARP 1/2inhibitor; Optune, a portable device that delivers tumor treating fields; and Qinlock, a switch-control tyrosine kinase inhibitor.
Type
Public
Status
Active
Founded
2014
HQ
CN | view all locations
Website
http://www.zailaboratory.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key people

  • Samantha Du

    Samantha Du, Founder, Chair and Chief Executive Officer

  • Harald Reinhart

    Harald Reinhart, Chief Medical Officer, Autoimmune and Infectious Diseases

  • Billy Cho

    Billy Cho, Chief Financial Officer

  • F. Ty Edmondson

    F. Ty Edmondson, Chief Legal Officer

LocationsView all

7 locations detected

  • Shang Hai Shi HQ

    China

    Jin Ke Lu, Pu Dong Xin Qu

  • Cambridge, MA

    United States

    314 Main St 4th 100

  • Menlo Park, CA

    United States

    1440 O'Brien Dr ste a & c

  • Suzhou, Jiangsu Sheng

    China

    Building 7&8 Biobay 218 Sangtian Street Suzhou

  • Bei Jing Shi

    China

    Xi Da Wang Lu, Chao Yang Qu

  • Hong Kong, Hong Kong Island

    Hong Kong

    Room 2301 , 23/F. Island Place Tower 510 King 's Road

and 1 others

ZAI Lab Financials

Summary financials

Revenue (Q3, 2022)
$57.5M
Gross profit (Q3, 2022)
$39.7M
Net income (Q3, 2022)
($161.2M)
Cash (Q3, 2022)
$1.1B
EBIT (Q3, 2022)
($165.1M)
Enterprise value
$3.5B

Footer menu